Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
RESEARCH TOOLSreports
Knight Therapeutics (GUD) Stock Price & Analysis
81 Followers
GUD Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$4.35 - C$6.22
Previous CloseC$5.7
Volume29.86K
Average Volume (3M)55.95K
Market Cap
C$577.57M
Enterprise ValueC$473.39M
Total Cash (Recent Filing)C$174.27M
Total Debt (Recent Filing)C$70.09M
Price to Earnings (P/E)―
Beta0.36
Next Earnings
Aug 08, 2024EPS Estimate
C$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding101,375,922
10 Day Avg. Volume62,605
30 Day Avg. Volume55,950
Standard Deviation0.06
R-Squared0.13
Alpha-0.00518
Financial Highlights & Ratios
Price to Book (P/B)1.43
Price to Sales (P/S)1.68
Price to Cash Flow (P/CF)4.50
P/FCF Ratio6.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$7.06Price Target Upside24.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Knight Therapeutics News
PremiumPress Releases
Knight Announces Normal Course Issuer Bid
PremiumCompany Announcements
Knight Therapeutics Announces Q1 Growth and Expansion
PremiumCompany Announcements
Knight Therapeutics Shareholders Back Directors and AuditorsOptions Prices
Currently, No data available
---
Ownership Overview
88.10% Insiders
1.94% Mutual Funds
0.86% Other Institutional Investors
9.10% Public Companies and
Individual Investors
GUD FAQ
What was Knight Therapeutics’s price range in the past 12 months?
Knight Therapeutics lowest stock price was C$4.35 and its highest was C$6.22 in the past 12 months.
What is Knight Therapeutics’s market cap?
Currently, no data Available
When is Knight Therapeutics’s upcoming earnings report date?
Knight Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 15 days.
How were Knight Therapeutics’s earnings last quarter?
Knight Therapeutics released its earnings results on May 09, 2024. The company reported -C$0.04 earnings per share for the quarter, missing the consensus estimate of C$0.013 by -C$0.053.
Is Knight Therapeutics overvalued?
According to Wall Street analysts Knight Therapeutics’s price is currently Undervalued.
Does Knight Therapeutics pay dividends?
Knight Therapeutics does not currently pay dividends.
What is Knight Therapeutics’s EPS estimate?
Knight Therapeutics’s EPS estimate is C$0.02.
How many shares outstanding does Knight Therapeutics have?
Knight Therapeutics has 101,327,290 shares outstanding.
What happened to Knight Therapeutics’s price movement after its last earnings report?
Knight Therapeutics reported an EPS of -C$0.04 in its last earnings report, missing expectations of C$0.013. Following the earnings report the stock price went up 3.041%.
Which hedge fund is a major shareholder of Knight Therapeutics?
Currently, no hedge funds are holding shares in TSE:GUD
---
Knight Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$7.06 (24.08% Upside)
C$7.06 (24.08% Upside)
Insider Transactions
Sold Shares
Worth $557.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.23%
12-Months-Change
Fundamentals
Return on Equity
-2.18%
Trailing 12-Months
Asset Growth
-7.32%
Trailing 12-Months
Company Description
Knight Therapeutics
Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.
---
GUD Earnings Call
Q1 2024
0:00 / 0:00
---
GUD Stock 12 Month Forecast
Average Price Target
C$7.06
▲(24.08% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alnylam Pharma
―
ANI Pharmaceuticals
―
Avadel Pharmaceuticals
―
Knight Therapeutics
―
Best Analysts Covering GUD
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
-2.98%
reiterated a buy rating 3 months ago
Copying Douglas Miehm's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -2.98% per trade.
---